

Basic science (August 2005)

1. Aupperlee MD, Smith KT, Kariagina A, Haslam SZ. Progesterone receptor isoforms A and B: temporal and spatial differences in expression during murine mammary gland development. *Endocrinology* 2005; **146**: 3577–3588.
2. Bar-Sinai A, Bassa N, Fischette M, Gottesman MM, Love DC, Hanover JA, Hochman J. Mouse mammary tumor virus env-derived peptide associates with nucleolar targets in lymphoma, mammary carcinoma, and human breast cancer. *Cancer Res* 2005; **65**: 7223–7230.
3. Berteaux N, Lottin V, Monte D, Pinte S, Quatannens B, Coll J, Hondermarck H, Curgy JJ, Dugimont T, Adriaenssens E. H19 mRNA-like noncoding RNA promotes breast cancer cell proliferation through positive control by E2F1. *J Biol Chem* 2005; **280**: 29625–29636.
4. Biroccio A, D'Angelo C, Jansen B, Cleave ME, Zupi G. Antisense clusterin oligodeoxynucleotides increase the response of HER-2 gene amplified breast cancer cells to trastuzumab. *J Cell Physiol* 2005; **204**: 463–469.
5. Bogdanova N, Enssen-Dubrowskaja N, Feshchenko S, Lazjuk GI, Rogov YI, Dammann O, Bremer M, Karstens JH, Sohn C, Dork T. Association of two mutations in the CHEK2 gene with breast cancer. *Int J Cancer* 2005; **116**: 263–266.
6. Cabioglu N, Yazici MS, Arun B, Broglio KR, Hortobagyi GN, Price JE, Sahin A. CCR7 and CXCR4 as novel biomarkers predicting axillary lymph node metastasis in T-1 breast cancer. *Clin Cancer Res* 2005; **11**: 5686–5693.
7. Ceschi M, Sun CL, Van Den Berg D, Koh WP, Yu MC, Probst-Hensch N. The effect of cyclin D1 (CCND1) G870A-polymorphism on breast cancer risk is modified by oxidative stress among Chinese women in Singapore. *Carcinogenesis* 2005; **26**: 1457–1464.
8. Chen B, Pan HY, Zhu LY, Deng Y, Pollard JW. Progesterone inhibits the estrogen-induced phosphoinositide 3-Kinase → AKT → GSK-beta 3 → Cyclin D1 → pRB pathway to block uterine epithelial cell proliferation. *Mol Endocrinol* 2005; **19**: 1978–1990.
9. Cook AC, Tuck AB, McCarthy S, Turner JG, Irby RB, Bloom GC, Yeatman TJ, Chambers AF. Osteopontin induces multiple changes in gene expression that reflect the six 'hallmarks of cancer' in a model of breast cancer progression. *Mol Carcinogen* 2005; **43**: 225–236.
10. DeMichele A, Aplenc R, Botbyl J, Colligan T, Wray L, Klein-Cabral M, Foulkes A, Gimotty P, Glick J, Weber B, Stadtmauer E, Rebbeck TR. Drug-metabolizing enzyme polymorphisms predict clinical outcome in a node-positive breast cancer cohort. *J Clin Oncol* 2005; **23**: 5552–5559.
11. Dietel M, Lewis MA, Shapiro S. Hormone replacement therapy: pathobiological aspects of hormone-sensitive cancers in women relevant to epidemiological studies on HRT: a mini-review. *Hum Reprod* 2005; **20**: 2052–2060.
12. Dote H, Cerna D, Burgan CE, Camphausen K, Tofilon PJ. ErbB3 expression predicts tumor cell radiosensitization induced by Hsp90 inhibition. *Cancer Res* 2005; **65**: 6967–6975.
13. Ewan KBR, Oketch-Rabah HA, Ravani SA, Shyamala G, Moses HL, Barcellos-Hoff MH. Proliferation of estrogen receptor-alpha-positive mammary epithelial cells is restrained by transforming growth factor-beta 1 in adult mice. *Am J Pathol* 2005; **167**: 409–417.
14. Fernandez CA, Yan L, Lous G, Yang J, Kutok JL, Moses MA. The matrix metalloproteinase-9/neutrophil gelatinase-associated lipocalin complex plays a role in breast tumor growth and is present in the urine of breast cancer patients. *Clin Cancer Res* 2005; **11**: 5390–5395.
15. Freedman ML, Penney KL, Stram DO, Riley S, McKean-Cowdin R, Le Marchand L, Altshuler D, Haiman CA. A haplotype-based case-control study of BRCA1 and sporadic breast cancer risk. *Cancer Res* 2005; **65**: 7516–7522.
16. Garcia MJ, Pole JCM, Chin SF, Teschendorff A, Naderi A, Ozdag H, Vias M, Kranjac T, Subkhankulova T, Paish C, Ellis I, Brenton JD,

- Edwards PAW, Caldas C. A 1Mb minimal amplicon at 8p11–12 in breast cancer identifies new candidate oncogenes. *Oncogene* 2005; **24**: 5235–5245.
17. Hu M, Yao J, Cai L, Bachman KE, van den Brule F, Velculescu V, Polyak K. Distinct epigenetic changes in the stromal cells of breast cancers. *Nat Genet* 2005; **37**: 899–905.
 18. Indik S, Gunzburg WH, Salmons B, Rouault F. Mouse mammary tumor virus infects human cells. *Cancer Res* 2005; **65**: 6651–6659.
 19. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M, Menard S, Palazzo JP, Rosenberg A, Musiani P, Volinia S, Nenci I, Calin GA, Querzoli P, Negrini M, Croce CM. MicroRNA gene expression deregulation in human breast cancer. *Cancer Res* 2005; **65**: 7065–7070.
 20. Jiang WG, Davies G, Martin T, Parr C, Watkins G, Mason MD, Mokbel K, Mansel RE. Targeting matrilysin and its impact on tumor growth *in vivo*: the potential implications in breast cancer therapy. *Clin Cancer Res* 2005; **11**: 6012–6019.
 21. Karsan A, Eigl BJ, Flibotte S, Gelmon K, Switzer P, Hassell P, Harrison D, Law J, Hayes M, Stillwell M, Xiao Z, Conrads TP, Veenstra T. Analytical and preanalytical biases in serum proteomic pattern analysis for breast cancer diagnosis. *Clin Chem* 2005; **51**: 1525–1528.
 22. Keen JC, Zhou Q, Park BH, Pettit C, Mack KM, Blair B, Brenner K, Davidson NE. Protein phosphatase 2A regulates estrogen receptor alpha (ER) expression through modulation of ER mRNA stability. *J Biol Chem* 2005; **280**: 29519–29524.
 23. Kim H, Laing M, Muller W. c-Src-null mice exhibit defects in normal mammary gland development and ER alpha signaling. *Oncogene* 2005; **24**: 5629–5636.
 24. Koblinski JE, Kaplan-Singer BR, VanOsdol SJ, Wu M, Engbring JA, Wang SL, Goldsmith CM, Piper JT, Vostal JG, Harms JF, Welch DR, Kleinman HK. Endogenous osteonectin/SPARC/BM-40 expression inhibits MDA-MB-231 breast cancer cell metastasis. *Cancer Res* 2005; **65**: 7370–7377.
 25. Le Marchand L, Donlon T, Kolonel LN, Henderson BE, Wilkens LR. Estrogen metabolism-related genes and breast cancer risk: the multi-ethnic cohort study. *Cancer Epidemiol Biomarkers* 2005; **14**: 1998–2003.
 26. Lesueur F, Pharoah PD, Laing S, Ahmed S, Jordan C, Smith PL, Luben R, Wareham NJ, Easton DF, Dunning AM, Ponder BAJ. Allelic association of the human homologue of the mouse modifier Ptprij with breast cancer. *Hum Mol Genet* 2005; **14**: 2349–2356.
 27. Liang YY, Hyder SM. Proliferation of endothelial and tumor epithelial cells by progestin-induced vascular endothelial growth factor from human breast cancer cells: paracrine and autocrine effects. *Endocrinology* 2005; **146**: 3632–3641.
 28. Lopez JI, Camenisch TD, Stevens MV, Sands BJ, McDonald J, Schroeder JA. CD44 attenuates metastatic invasion during breast cancer progression. *Cancer Res* 2005; **65**: 6755–6763.
 29. Luo M, Koh M, Feng JJ, Wu Q, Melamed P. Cross talk in hormonally regulated gene transcription through induction of estrogen receptor ubiquitylation. *Mol Cell Biol* 2005; **25**: 7386–7398.
 30. Mann GB, Fahey VD, Feleppa F, Buchanan MR. Reliance on hormone receptor assays of surgical specimens may compromise outcome in patients with breast cancer. *J Clin Oncol* 2005; **23**: 5148–5154.
 31. Melkounian ZK, Peng X, Gan BY, Wu YY, Guan JL. Mechanism of cell cycle regulation by FIP200 in human breast cancer cells. *Cancer Res* 2005; **65**: 6676–6684.
 32. Oliva J, El Messaoudi S, Pellestor F, Fuentes M, Georget V, Balaguer P, Cavailles V, Vignon FO, Badia E. Involvement of HP1 alpha protein in irreversible transcriptional inactivation by antiestrogens in breast cancer cells. *Febs Lett* 2005; **579**: 4278–4286.
 33. Radvanyi L, Singh-Sandhu D, Gallichan S, Lovitt C, Pedyczak A, Mallo G, Gish K, Kwok K, Hanna W, Zubovits J, Armes J, Venter D, Hakimi J, Shortreed J, Donovan M, Parrington M, Dunn P, Oomen R, Tartaglia J, Berinstein NL. The gene associated with trichorhinophalangeal syndrome in humans is overexpressed in breast cancer. *Proc Natl Acad Sci* 2005; **102**: 11005–11010.
 34. Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, Hess KR, Stec J, Ayers M, Wagner P, Morandi P, Fan C, Rabiul I, Ross JS, Hortobagyi GN, Pusztai L. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. *Clin Cancer Res* 2005; **11**: 5678–5685.
 35. Shah YM, Al-Dhaheri M, Dong Y, Ip C, Jones FE, Rowan BG. Selenium disrupts estrogen receptor alpha signaling and potentiates tamoxifen antagonism in endometrial cancer cells and tamoxifen-resistant breast cancer cells. *Mol Cancer Ther* 2005; **4**: 1239–1249.
 36. Shalom-Feuerstein R, Cooks T, Raz A, Kloog Y. Galectin-3 regulates a molecular switch from N-Ras to K-Ras usage in human breast carcinoma cells. *Cancer Res* 2005; **65**: 7292–7300.
 37. Stassi G, Garofalo M, Zerilli M, Ricci-Vitiani L, Zanca C, Todaro M, Aragona F, Limite G, Petrella G, Condorelli G. PED mediates AKT-dependent chemoresistance in human

- breast cancer cells. *Cancer Res* 2005; **65**: 6668–6675.
38. Sun Y, Strizzi L, Raafat A, Hirota M, Bianco C, Feigenbaum L, Kenney N, Wechselberger C, Callahan R, Salomon DS. Overexpression of human Cripto-1 in transgenic mice delays mammary gland development and differentiation and induces mammary tumorigenesis. *Am J Pathol* 2005; **167**: 585–597.
39. Tu Y, Jerry DJ, Pazik B, Schneider SS. Sensitivity to DNA damage is a common component of hormone-based strategies for protection of the mammary gland. *Mol Cancer Res* 2005; **3**: 435–442.
40. Ursin G, Bernstein L, Lord SJ, Karim R, Deapen D, Press MF, Daling JR, Norman SA, Liff JM, Marchbanks PA, Folger SG, Simon MS, Strom BL, Burkman RT, Weiss LK, Spirtas R. Reproductive factors and subtypes of breast cancer defined by hormone receptor and histology. *Br J Cancer* 2005; **93**: 364–371.
41. van der Hel OL, Bueno-de-Mesquita HB, van Gils CH, Roest M, Slothouber B, Grobbee DE, Peeters PHM. Cumulative genetic defects in carcinogen metabolism may increase breast cancer risk. *Cancer Cause Contr* 2005; **16**: 675–681.
42. Varma AK, Brown RS, Birrane G, Ladas JAA. Structural basis for cell cycle checkpoint control by the BRCA1-CtIP complex. *Biochemistry* 2005; **44**: 10941–10946.
43. Wang CG, Fan SJ, Li ZP, Fu MF, Rao M, Ma YX, Lisanti MP, Albanese C, Katzenellenbogen BS, Kushner PJ, Weber B, Rosen EM, Pestell RG. Cyclin D1 antagonizes BRCA1 repression of estrogen receptor alpha activity. *Cancer Res* 2005; **65**: 6557–6567.
44. Wittmann BM, Fujinaga K, Deng HY, Ogba N, Montano MM. The breast cell growth inhibitor, estrogen down regulated gene 1, modulates a novel functional interaction between estrogen receptor alpha and transcriptional elongation factor cyclin T1. *Oncogene* 2005; **24**: 5576–5588.
45. Yuan JM, Koh WP, Sun CL, Lee HP, Yu MC. Green tea intake, ACE gene polymorphism and breast cancer risk among Chinese women in Singapore. *Carcinogenesis* 2005; **26**: 1389–1394.
46. Zhang SM, Hankinson SE, Hunter DJ, Giovannucci EL, Colditz GA, Willett WC. Folate intake and risk of breast cancer characterized by hormone receptor status. *Cancer Epidem Biomar* 2005; **14**: 2004–2008.
47. Zhao H, Cui YZ, Dupont J, Sun H, Hennighausen L, Yakar S. Overexpression of the tumor suppressor gene phosphatase and tensin homologue partially inhibits Wnt-1-induced mammary tumorigenesis. *Cancer Res* 2005; **65**: 6864–6873.

Prepared by
R. Sutherland, J. Scorer
Cancer Research Program
Garvan Institute of Medical Research
Darlinghurst, NSW, Australia